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CASE REPORT
High altitude‑related hypertensive crisis 
and acute kidney injury in an asymptomatic 
healthy individual
Edward Gilbert‑Kawai1, Daniel Martin1*, Michael Grocott1,2 and Denny Levett1,2
Abstract 
Background: High‑altitude exposure causes a mild to moderate rise in systolic and diastolic blood pressure. This case 
report describes the first documented case of a hypertensive crisis at altitude, as well as the first report of the occur‑
rence of acute kidney injury in the context of altitude‑related hypertension.
Case presentation: A healthy, previously normotensive 30‑year old, embarked on a trek to Everest Base Camp 
(5300 m). During his 11‑day ascent the subject developed increasingly worsening hypertension. In the absence of 
symptoms, the individual initially elected to remain at altitude as had previously been the plan. However, an increase 
in the severity of his hypertension to a peak of 223/119 mmHg resulted in a decision to descend. On descent he 
was found to have an acute kidney injury that subsequently resolved spontaneously. His blood pressure reverted to 
normal at sea level and subsequent investigations including a transthoracic echocardiogram, cardiac magnetic reso‑
nance imaging, renal ultrasound, and urinary catecholamines were normal.
Conclusion: This report challenges the view that transient rises in blood pressure at altitude are without immediate 
risk. We review the evidence that altitude induces hypertension and discuss the implications for the management of 
hypertension at altitude.
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Background
Hypertension is defined as a blood pressure (BP) above 
140/90 mmHg [1]. Acute exposure to high altitude causes 
a mild-to-moderate increase in both systolic (SBP) and 
diastolic (DBP) blood pressure although there is marked 
inter-individual variability in the response [2, 3]. The 
increase is usually transient, and is evident in both 
healthy individuals and those with pre-existing hyper-
tension [4]. ‘Severe hypertension’ is defined as having a 
systolic BP ≥ 180 mmHg, or a diastolic BP ≥ 110 mmHg. 
Acute severe hypertension is also referred to as a ‘hyper-
tensive crises’ or ‘hypertensive emergency’ if associ-
ated with acute end-organ damage, or as ‘hypertensive 
urgency’ in the absence of acute end-organ damage [1, 5]. 
This case report describes the development of a hyper-
tensive crisis with acute kidney injury in a previously 
healthy 30-year old. Implications for the management of 
hypertension at high altitude are discussed.
Case presentation
A 30-year-old Caucasian male, normally resident at sea 
level with no previous medical history, embarked on a 
trek to Everest Base Camp (EBC) (5300 m) as an inves-
tigator on the Xtreme Everest 2 research expedition [6]. 
His blood pressure had been measured at sea level as part 
of the physiological research investigations and he was 
normotensive (126/82 mmHg). He had no cardiovascular 
risk factors for hypertension. As part of the data collec-
tion during the research expedition his blood pressure, 
heart rate, respiratory rate and the saturation of periph-
eral arterial blood with oxygen (‘oxygen saturation’) were 
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measured in a standardized fashion each morning after 
5 min of seated rest [7] (Table 1). The subject was blinded 
to the blood pressure measurements, whereby the mean 
of three resting readings was recorded (M3W, Omron, 
Japan), and oxygen saturation was measured using a 
pulse oximeter placed on the individual’s dominant fore-
finger (Nonin Onyx, Minnesota, USA).
During his ascent to EBC, the subject reported mini-
mal symptoms of acute mountain sickness (AMS) that 
did not require treatment, and was otherwise well. The 
subject was reviewed by the expedition medical officer 
on arrival at EBC because his hypertension was per-
sistent. To confirm the accuracy of the blood pres-
sure readings taken with the automated oscillometric 
blood pressure monitor, measurements were made with 
another electronic device (Tango+, SunTech Medical, 
USA) and using a manual sphygmomanometer. Since 
the three methods produced consistent results (observed 
to be within 5 mmHg of each other on repeated record-
ings), the Omron was subsequently used for all measure-
ments. The subject remained asymptomatic and physical 
examination, electrocardiogram (ECG) and urine analy-
sis were normal. Unfortunately due to equipment failure 
we were unable to examine the subject for signs of retinal 
haemorrhage or papilloedema. In the absence of symp-
toms, and after discussion with the expedition medical 
team and a review of the literature, he initially decided to 
remain at altitude with twice-daily blood pressure moni-
toring in the expectation that the increase in BP would be 
transient as has previously been reported [8].
After 5  days at EBC, the subject’s diastolic BP 
increased above 110  mmHg (173/114), and a diagno-
sis of severe hypertension was made (see Fig. 1). Whilst 
his DBP decreased on the subsequent 2  days, (107 and 
109  mmHg), his SBP continued to increase reaching 
180  mmHg by day seven at EBC. A peak blood pres-
sure of 223/119  mmHg was recorded on day seventeen 
at EBC. Although he remained asymptomatic, end-organ 
damage could not be excluded in the field. As a result, the 
decision was made that he should descend back to Kath-
mandu for further investigation and for the instigation of 
treatment as required.
The subject’s blood pressure improved on descent 
to Kathmandu, but he remained hypertensive initially 
with a resting blood pressure of 148/91 mmHg. Physical 
examination was normal as was his ECG. Blood results 
showed evidence of acute kidney injury (AKI) with a urea 
of 16.2 mmol/L and a creatinine of 168 μmol/L [9], and 
urine dipstix demonstrated ‘2+’ of protein (correspond-
ing to a semi-quantitative value of 100  g/l), and ‘2+’ of 
blood. Using the Cockcroft–Gault equation, his esti-
mated creatinine clearance was 68.3  ml/min [10]. Fur-
ther investigations included an echocardiogram (ECHO) 
‘trace mitral regurgitation, trace tricuspid regurgitation, 
otherwise normal’, and renal ultrasound ‘normal renal 
Doppler study with no evidence to suggest renal artery 
stenosis’. Repeat testing 1  week after descent demon-
strated a blood pressure of 143/89  mmHg, and normal 
renal function (creatinine 80 μmol/L, urea 6.8 mmol/L). 
Investigations for other secondary causes of hyperten-
sion were not available in Nepal and with his return to 
London imminent further follow-up was delayed until his 
repatriation. Investigations in the UK revealed normal 
24-h BP monitoring (mean BP 124/84  mmHg), normal 
transthoracic ECHO and cardiac magnetic resonance 
imaging (MRI), a normal renal ultrasound, normal renal 
Table 1 Physiological variables at rest during ascent to altitude
Subjects initially flew from London (day 0) to Kathmandu (day 1). They then flew to Lukla (2850 m) (day 2) before trekking to Everest Base Camp (5300 m) over 11 days
Day (altitude in metres) Blood pressure (mmHg) Heart rate (beats/min) Ventilatory rate (breaths/min) SpO2 (%)
0 (50) 126/82 64 9 99
1 (1300) 132/87 68 13 98
2 (2850) 134/88 66 15 96
3 (3500) 146/91 68 10 93
4 (3500) 158/93 70 13 94
5 (3500) 151/91 64 8 92
6 (3770) 140/93 83 9 89
7 (4250) 147/95 68 13 90
8 (4250) 142/84 72 11 84
9 (4250) 157/93 64 11 86
10 (4950) 148/96 76 10 88
11 (5160) 143/92 71 11 82
12 (5300) 146/97 71 14 76
13 (5300) 167/106 63 15 77
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function, normal urinary catecholamines and no abnor-
malities on fundoscopy.
Discussion
This is the first report of a hypertensive crisis at alti-
tude and the first report of AKI occurring in the context 
of hypertension at altitude. The case illustrates an indi-
vidual who experienced large and persistent increases 
in both SBP and DBP on exposure to high altitude with 
subsequent reversion of the values towards normal upon 
descent to lower altitude. Furthermore, this caution-
ary case suggests that contrary to current opinion [2], 
altitude-induced hypertension may be associated with 
end-organ damage and it is plausible that this relation-
ship may be causal. It is noteworthy that our subject was 
asymptomatic so had he not been a research subject his 
renal impairment may have progressed unchecked. Renal 
pathology per se may be a cause of malignant hyperten-
sion, and renal parenchymal disease accounts for up 
to 80 % of all secondary causes at sea level [11]. Conse-
quently, it is possible that the renal dysfunction occurred 
first causing a secondary increase in blood pressure. We 
consider this scenario unlikely as the subject had normal 
renal function prior to departure (creatinine 88 μmol/L, 
urea 6.8 mmol/L), and his renal function returned to nor-
mal 1 week after returning to Kathmandu when his blood 
pressure normalized. Moreover, acute renal failure sec-
ondary to increased hydrostatic pressures is a common 
sequelae of hypertensive crises [12].
Whilst the prevalence of hypertension in North Ameri-
can and European adults has been reported as high as 
44  % [13, 14], comparatively little information exists 
describing the effects of altitude on blood pressure. Fur-
thermore, the existing literature is inconsistent. In non-
hypertensive patients acutely exposed to hypoxia, several 
studies demonstrate increased pressures [15–17], and 
others describe decreased pressures [8], whilst some 
report no change [18, 19]. Similarly in patients with pre-
existing hypertension, numerous studies report eleva-
tions in blood pressure upon acute exposure to varying 
altitudes [17, 20–23] yet others’ reports no significant 
change [17, 18, 24]. In 2009, the literature was summa-
rized [2], and having taken into account the discrepan-
cies between study methodologies, the author concluded 
that whilst it was difficult to draw conclusions about 
blood pressure responses in hypertensive patients trav-
elling to elevations above 3500  m, acute ascent to high 
altitude below this height causes a modest rise in blood 
pressure in patients with pre-existing mild to moderate 
hypertensions.
The risks of altitude-induced hypertension are cur-
rently unclear. There is no evidence to support an 
Fig. 1 Subject’s systolic, diastolic and mean arterial blood pressure throughout the expedition. SBP systolic blood pressure, DBP diastolic blood 
pressure, MAP mean arterial pressure
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association between increased pressures and hyperten-
sive complications such as hypertensive retinopathy, 
intracranial bleeding, or myocardial infarction [2, 22–24] 
or AMS [2]. However, the available data are very limited 
and the absence of published data should not be inter-
preted as implying that there is no increased risk. Con-
sequently, the risk of short- and long-term complications 
of hypertensive episodes at altitude cannot, currently, be 
reliably estimated.
Inconsistencies in the current literature may reflect 
marked inter-individual variability in the hypertensive 
response to altitude—a point highlighted recently in the 
Consensus statement of the Medical Commission of 
the Union Internationale des Associations d’Alpinisme 
[25]. Furthermore, it is difficult to separate the effect of 
altitude on blood pressure from the multitude of other 
potentially confounding factors including ascent rate, 
altitude sickness, dehydration, temperature and stress 
associated with an environmental change [4, 25, 26]. 
Consequently, a large prospective dataset of both nor-
motensive and hypertensive individuals with a controlled 
ascent profile (hypoxic exposure) is required to clarify 
the altitude threshold, incidence, severity, duration and 
reversibility of any hypertensive effect. A study of this 
nature would also permit further evaluation of both the 
cardiovascular risk and the risk of end-organ damage 
with altitude-related hypertension [11]. Such evidence is 
not currently available, but in the context of expanding 
tourism with an increasingly elderly tourist population, 
the need for accurate data to direct treatment for known 
hypertensives and to permit valid risk counselling prior 
to travel is increasingly important [2].
At sea level, guidelines for the management of severe 
hypertension suggest starting antihypertensive drug 
treatment immediately, and same day, after hospi-
tal admission if signs of papilloedema and/or retinal 
haemorrhage (hypertensive retinopathy) are present 
[1]. At altitude the prevalence of severe hypertension is 
unknown and there are no guidelines to direct treatment. 
There is evidence to support the occurrence of hyper-
tension at altitude, but the literature is inconsistent and 
the precise incidence and severity of the hypertensive 
response to altitude are not known [3, 27, 28]. Further-
more, the implications of altitude-induced hypertension 
for cardiovascular risk and end-organ damage require 
clarification.
Unfortunately, we are unable to accurately predict 
which individuals will respond in this way to altitude and 
screening all individuals at altitude would be impracti-
cal. However, monitoring blood pressure and possibly 
medication adjustments should be recommended in 
some individuals. Certainly any individual with poorly 
controlled or labile hypertension or who has previously 
had a marked hypertensive response to altitude should 
be encouraged to self-monitor during ascent to altitude. 
Such patients should be given clear advice about adjust-
ing medication doses in the event of a severe persistent 
hypertensive response. It has previously been suggested 
that medication adjustments in known hypertensive 
patients at altitude should be considered in accordance 
with sea-level practices for patients with hypertensive 
urgency or emergency at altitude [2], namely:
1. If SBP is greater than 180 mmHg or BDP is greater 
than 120 mmHg and there is evidence of side effects 
from these elevated pressures, including vision 
changes, shortness of breath, chest pain, or altered 
mental status.
2. SBP is greater than 220 mmHg or DBP is greater than 
140 mmHg in the absence of symptoms.
Given the possibility of end-organ damage that our 
case illustrates, we suggest that descent should also be 
considered in these circumstances if there is not an 
immediate response to increasing antihypertensive medi-
cations. Furthermore, in patients who are not known to 
have hypertension, we would suggest that immediate 
descent should be recommended in the two scenarios 
outlined above. Commencing new anti-hypertensives in 
a remote environment, with no knowledge of underlying 
renal function nor having the ability to predict or moni-
tor possible renal injury, cannot be recommended.
Ultimately, given the increasing popularity of high-
altitude travel and the relatively high incidence of hyper-
tension, further research is warranted to evaluate this 
problem. Studies should focus on identifying risk factors 
for large increases in blood pressure, and in particular, 
whether a hypoxic stimulus at sea level predicts the alti-
tude hypertensive response. In addition the persistence 
of altitude-induced hypertension on return to normoxia 
should be evaluated, as should implications for future 
hypertensive risk at sea level. Finally, clinical trials to 
determine the most appropriate treatment for clinically 
significant blood pressure elevations in this environment 
are needed.
Conclusion
This case report is the first documented case of a hyper-
tensive crisis at altitude as well as the first report of the 
occurrence of AKI in the context of altitude-related 
hypertension. This report challenges the view that tran-
sient rises in blood pressure at altitude are without 
immediate risk. Further studies are needed to identify 
the prevalence of severe hypertension at altitude, to 
identify risk factors and to clarify the most appropri-
ate treatment. In the absence of sufficient evidence, we 
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recommend a conservative approach of screening at risk 
patients, increasing medication in known hypertensives 
with severe hypertension, and consideration of descent 
in previously normotensive subjects who develop severe 
and sustained hypertension.
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